Printer Friendly

Abbott Laboratories Introduces Two New Assays for Therapeutic Drug Monitoring Management.

- Monitoring Blood Levels Important to Preventing Ineffective Medication or Toxic Side Effects -

Abbott Laboratories announced today the addition of two new assays to its therapeutic drug monitoring (TDM) test menu for use on Abbott's ARCHITECT(R) c8000(TM), ARCHITECT ci8200(TM) and AEROSET(R) immunochemistry systems. Abbott's MULTIGENT(TM) digoxin assay monitors levels of an anti-arrhythmic drug used in patients with heart problems, while Abbott's MULTIGENT valproic acid assay checks for levels of a commonly used anticonvulsant drug. Both assays are easy to use, provide precise and accurate results down to low drug levels and show minimal interference from other blood components. Both the MULTIGENT digoxin and MULTIGENT valproic acid assays provide customers with a convenient, ready-to-use liquid formulation.

"We continue to expand our TDM test menu for our clinical chemistry platforms," said William Brown, Ph.D., vice president, diagnostic assays and systems development, Abbott Laboratories. "These two assays offer excellent comparison to Abbott's other gold standard AxSYM(R) TDM tests."

The MULTIGENT digoxin assay utilizes a small sample size of 15 uL and provides rapid results with a 10-minute turnaround time. Sensitive and specific, the MULTIGENT digoxin assay has low cross reactivity to most metabolites. Additionally, this assay has minimal interference from endogenous blood components and no significant interference from spironolactone, a diuretic, or its metabolite, canrenone. The MULTIGENT digoxin assay features an on-board reagent stability and calibration stability of 60 days.

The MULTIGENT valproic acid assay uses a small sample size of 4 uL and provides rapid results with a 10-minute turnaround time. This assay is also sensitive and specific with minimal interference from endogenous blood components. The MULTIGENT valproic acid assay offers an on-board reagent stability of 54 days and calibration stability of 27 days.

"Today, pharmaceuticals provide tremendous benefits for patients. However, too much or too little of some drugs can negatively impact the patient's health. That's why it's important to be able to use therapeutic monitoring to help manage certain drugs," said Steven H. Wong, Ph.D., professor of Pathology, and director, Clinical Chemistry/Toxicology, TDM, Pharmacogenomics and Proteomics, Medical College of Wisconsin.

Adverse reactions to high levels of digoxin may include ventricular problems such as premature contraction, fibrillation or tachycardia. Digoxin also can cause nausea, vomiting, tremors and anorexia. Valproic acid adverse reactions may include nausea, vomiting, tremors, drowsiness, mild ataxia and hyperammonemia.

About the ARCHITECT c8000 system

The ARCHITECT c8000 system can run up to 1,200 clinical chemistry tests an hour selected from a menu of 68 assays. It provides the convenience of a multiple sample loading capacity of 150 specimens which may include a mixture of serum, plasma, urine and cerebrospinal fluid.

About the ARCHITECT ci8200 system

Combining immunoassay and clinical chemistry on one integrated platform, the ci8200 system runs up to 200 immunoassay tests and up to 1,200 clinical chemistry tests an hour. By consolidating both immunoassay and clinical chemistry testing capabilities, the ci8200 helps improve laboratory productivity and efficiency.

About the AEROSET system

The AEROSET clinical chemistry system can run up to 2,000 tests per hour providing laboratories with a high level of throughput and reduced turnaround time. This automated system accommodates up to 230 patient samples.

About Abbott Laboratories

Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 55,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com/ .

CONTACT: Media, Amy Woodworth, +1-847-935-4755, or Financial Community, Christy Wistar, +1-847-938-4475, both of Abbott Laboratories

Web site: http://www.abbott.com/

Company News On-Call: http://www.prnewswire.com/comp/110328.html
COPYRIGHT 2004 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:May 20, 2004
Words:626
Previous Article:Corio Passes SAS 70 Type II Audit.
Next Article:Webcast Alert: Alliant Energy Corporation Annual Meeting of Shareowners.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters